MA52888A - BENZENE SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS - Google Patents
BENZENE SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTSInfo
- Publication number
- MA52888A MA52888A MA052888A MA52888A MA52888A MA 52888 A MA52888 A MA 52888A MA 052888 A MA052888 A MA 052888A MA 52888 A MA52888 A MA 52888A MA 52888 A MA52888 A MA 52888A
- Authority
- MA
- Morocco
- Prior art keywords
- therapeutic agents
- benzene sulfonamide
- sulfonamide compounds
- compounds
- benzene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684436P | 2018-06-13 | 2018-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52888A true MA52888A (en) | 2021-04-21 |
Family
ID=67138087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052888A MA52888A (en) | 2018-06-13 | 2019-06-13 | BENZENE SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10745392B2 (en) |
| EP (1) | EP3807281A1 (en) |
| JP (2) | JP7371029B2 (en) |
| KR (1) | KR20210019507A (en) |
| CN (1) | CN112262142B (en) |
| AU (1) | AU2019285184B2 (en) |
| BR (1) | BR112020024729A2 (en) |
| CA (1) | CA3103600A1 (en) |
| CL (1) | CL2020003197A1 (en) |
| CR (1) | CR20200613A (en) |
| EA (1) | EA202092719A1 (en) |
| EC (1) | ECSP20079861A (en) |
| IL (1) | IL278949B1 (en) |
| JO (1) | JOP20200304A1 (en) |
| MA (1) | MA52888A (en) |
| MX (1) | MX2020013317A (en) |
| NI (1) | NI202000098A (en) |
| PE (1) | PE20211389A1 (en) |
| PH (1) | PH12020552111A1 (en) |
| SA (1) | SA520420768B1 (en) |
| SG (1) | SG11202011862PA (en) |
| UA (1) | UA127024C2 (en) |
| WO (1) | WO2019241533A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017268006B2 (en) * | 2016-05-20 | 2021-03-11 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| RU2760303C2 (en) | 2016-12-09 | 2021-11-23 | Ксенон Фармасьютикалз Инк. | Benzenesulfonamide compounds and their use as therapeutic agents |
| CN112262142B (en) * | 2018-06-13 | 2023-11-14 | 泽农医药公司 | Benzenesulfonamide compounds and their use as therapeutic agents |
| CR20210099A (en) | 2018-08-31 | 2021-06-24 | Xenon Pharmaceuticals Inc | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5877193A (en) | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| ES2187024T3 (en) | 1997-05-07 | 2003-05-16 | Galen Chemicals Ltd | INTRAVAGINAL DRUG RELEASE DEVICE FOR TESTOSTERONE ADMINISTRATION AND TESTOSTERONE PRECURSORS. |
| DE69928286T2 (en) | 1999-01-13 | 2006-07-13 | Warner-Lambert Co. Llc | BENZENESULFONAMIDE DERIVATIVES AND THEIR USE AS MEK INHIBITORS |
| DE19907385A1 (en) | 1999-02-20 | 2000-08-24 | Boehringer Ingelheim Pharma | New 3-(phenoxy or phenylalkoxy)-2-phenyl-propylamines, useful for treating e.g. arrhythmia, spasms, pain or neurodegenerative diseases, are tension-dependent sodium channel blockers |
| CN1365277A (en) | 1999-07-16 | 2002-08-21 | 沃尼尔·朗伯公司 | Method for treating chronic pain using MEK inhibitors |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| FR2836917B1 (en) | 2002-03-11 | 2006-02-24 | Lipha | NITROSO DIPHENYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS MEDICAMENTS FOR THE TREATMENT OF DISEASES CHARACTERIZED BY OXIDATIVE STRESS SITUATION |
| EP1531815B1 (en) | 2002-06-27 | 2014-09-24 | Novo Nordisk A/S | Glucokinase activators |
| JP2005162726A (en) | 2003-01-24 | 2005-06-23 | Tanabe Seiyaku Co Ltd | Pyrazolopyrimidine compound and method for producing the same |
| WO2004092123A2 (en) | 2003-04-10 | 2004-10-28 | Microbia, Inc. | Inhibitors of fungal invasion |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| BRPI0412380A (en) | 2003-07-08 | 2006-09-19 | Novartis Ag | benzenesulfonylamino compounds and pharmaceutical compositions containing these |
| TW200524888A (en) | 2003-08-08 | 2005-08-01 | Vertex Pharma | Compositions useful as inhibitors of voltage-gated ion channels |
| HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| EP1888544A2 (en) | 2004-12-17 | 2008-02-20 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| KR20080053931A (en) | 2005-10-06 | 2008-06-16 | 사노피-아벤티스 | 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| KR20080081178A (en) | 2005-12-21 | 2008-09-08 | 버텍스 파마슈티칼스 인코포레이티드 | Heterocyclic derivatives as modulators of ion channels |
| KR101117931B1 (en) | 2006-08-15 | 2012-04-12 | 에프. 호프만-라 로슈 아게 | Phenyl, pyridine and quinoline derivatives |
| BRPI0717773A2 (en) | 2006-10-19 | 2013-11-05 | Signal Pharm Llc | COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHODS FOR TREATING OR PREVENTING CANCER, AN INFLAMMATORY CONDITION, IMMUNOLOGICAL CONDITION OR METHODOLOGICAL CONDITION, AND FOR INHIBITING A KINASE IN A CELL EXPRESSING DITA KINASE |
| WO2009012241A1 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| WO2009012242A2 (en) | 2007-07-13 | 2009-01-22 | Icagen, Inc. | Sodium channel inhibitors |
| WO2009013171A2 (en) | 2007-07-24 | 2009-01-29 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| WO2009099177A1 (en) | 2008-02-06 | 2009-08-13 | Taisho Pharmaceutical Co., Ltd. | Amino imidazole derivative |
| KR20110027657A (en) | 2008-06-25 | 2011-03-16 | 다이이찌 산쿄 가부시키가이샤 | Carboxylic acid compound |
| JP2011526919A (en) | 2008-07-01 | 2011-10-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | Heterocyclic derivatives as inhibitors of ion channels |
| US20110294853A1 (en) | 2008-09-12 | 2011-12-01 | Benjamin Pelcman | Bis Aromatic Compounds for Use in the Treatment of Inflammation |
| JP5053459B2 (en) | 2009-01-12 | 2012-10-17 | アイカジェン， インコーポレイテッド | Sulfonamide derivatives |
| EP2590951B1 (en) | 2010-07-09 | 2015-01-07 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| SG187742A1 (en) | 2010-08-20 | 2013-03-28 | Hutchison Medipharma Ltd | Pyrrolopyrimidine compounds and uses thereof |
| AU2012296529A1 (en) | 2011-08-17 | 2014-02-20 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| RU2014121489A (en) | 2011-10-28 | 2015-12-10 | Мерк Шарп И Доум Корп. | COMPOUNDS OF BENZOXAZOLINONE WITH SELECTIVE ACTIVITY REGARDING POTENTIAL DEPENDENT SODIUM CHANNELS |
| WO2013064983A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| US9481677B2 (en) | 2011-10-31 | 2016-11-01 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
| US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| US9346798B2 (en) | 2012-02-13 | 2016-05-24 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| AR091112A1 (en) | 2012-05-22 | 2015-01-14 | Genentech Inc | BENZAMIDAS N-REPLACED AS INHIBITORS OF THE SODIUM CHANNELS NAV1.7 |
| CA2887845C (en) | 2012-10-15 | 2020-12-15 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
| US9388179B2 (en) | 2012-10-26 | 2016-07-12 | Merck Sharp & Dohme Corp. | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels |
| KR20150074122A (en) | 2012-10-26 | 2015-07-01 | 머크 샤프 앤드 돔 코포레이션 | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
| TW201443025A (en) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | Chemical compounds |
| TW201512171A (en) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | Chemical compounds |
| US9212182B2 (en) | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| GB201310542D0 (en) | 2013-06-13 | 2013-07-31 | Antabio Sas | Compounds |
| WO2015035278A1 (en) | 2013-09-09 | 2015-03-12 | Bristol-Myers Squibb Company | RORγ MODULATORS |
| MY181928A (en) | 2013-09-10 | 2021-01-14 | Chromocell Corp | Sodium channel modulators for the treatment of pain and diabetes |
| EP3074377B1 (en) | 2013-11-27 | 2018-10-17 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| WO2015077905A1 (en) | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels |
| US9834543B2 (en) | 2013-12-23 | 2017-12-05 | Purdue Pharma L.P. | Indazoles and use thereof |
| WO2016177340A1 (en) | 2015-05-05 | 2016-11-10 | 上海海雁医药科技有限公司 | Bicyclic substituted benzene sulfonamide derivative, and preparation method and pharmaceutical use thereof |
| AU2016370677A1 (en) | 2015-12-18 | 2018-06-07 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| US10442778B2 (en) | 2016-03-22 | 2019-10-15 | Merck Sharp & Dohme Corp. | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels |
| AU2017268006B2 (en) | 2016-05-20 | 2021-03-11 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| MA46615A (en) | 2016-10-27 | 2019-09-04 | Bristol Myers Squibb Co | ACYL-SULFONAMIDE TYPE NAV1.7 INHIBITORS |
| WO2018093694A1 (en) | 2016-11-17 | 2018-05-24 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| RU2760303C2 (en) | 2016-12-09 | 2021-11-23 | Ксенон Фармасьютикалз Инк. | Benzenesulfonamide compounds and their use as therapeutic agents |
| CN112262142B (en) | 2018-06-13 | 2023-11-14 | 泽农医药公司 | Benzenesulfonamide compounds and their use as therapeutic agents |
| CR20210099A (en) | 2018-08-31 | 2021-06-24 | Xenon Pharmaceuticals Inc | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
| CN112638898B (en) | 2018-08-31 | 2024-04-09 | 泽农医药公司 | Heteroaryl substituted sulfonamide compounds and their use as sodium channel inhibitors |
-
2019
- 2019-06-13 CN CN201980039029.1A patent/CN112262142B/en active Active
- 2019-06-13 KR KR1020217000602A patent/KR20210019507A/en unknown
- 2019-06-13 CA CA3103600A patent/CA3103600A1/en active Pending
- 2019-06-13 US US16/440,459 patent/US10745392B2/en active Active
- 2019-06-13 PE PE2020001990A patent/PE20211389A1/en unknown
- 2019-06-13 WO PCT/US2019/037011 patent/WO2019241533A1/en unknown
- 2019-06-13 CR CR20200613A patent/CR20200613A/en unknown
- 2019-06-13 MX MX2020013317A patent/MX2020013317A/en unknown
- 2019-06-13 IL IL278949A patent/IL278949B1/en unknown
- 2019-06-13 AU AU2019285184A patent/AU2019285184B2/en active Active
- 2019-06-13 SG SG11202011862PA patent/SG11202011862PA/en unknown
- 2019-06-13 BR BR112020024729-4A patent/BR112020024729A2/en unknown
- 2019-06-13 EP EP19735024.2A patent/EP3807281A1/en active Pending
- 2019-06-13 UA UAA202008102A patent/UA127024C2/en unknown
- 2019-06-13 JP JP2020568796A patent/JP7371029B2/en active Active
- 2019-06-13 EA EA202092719A patent/EA202092719A1/en unknown
- 2019-06-13 MA MA052888A patent/MA52888A/en unknown
- 2019-12-13 JO JOP/2020/0304A patent/JOP20200304A1/en unknown
-
2020
- 2020-07-13 US US16/927,178 patent/US11325902B2/en active Active
- 2020-12-09 PH PH12020552111A patent/PH12020552111A1/en unknown
- 2020-12-09 CL CL2020003197A patent/CL2020003197A1/en unknown
- 2020-12-10 EC ECSENADI202079861A patent/ECSP20079861A/en unknown
- 2020-12-10 NI NI202000098A patent/NI202000098A/en unknown
- 2020-12-10 SA SA520420768A patent/SA520420768B1/en unknown
-
2023
- 2023-08-08 JP JP2023129150A patent/JP2023138672A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019285184B2 (en) | 2023-11-16 |
| JP7371029B2 (en) | 2023-10-30 |
| CA3103600A1 (en) | 2019-12-19 |
| IL278949B1 (en) | 2024-04-01 |
| US20200361927A1 (en) | 2020-11-19 |
| MX2020013317A (en) | 2021-04-13 |
| CL2020003197A1 (en) | 2021-04-30 |
| UA127024C2 (en) | 2023-03-15 |
| JP2021528387A (en) | 2021-10-21 |
| SG11202011862PA (en) | 2020-12-30 |
| PH12020552111A1 (en) | 2021-08-02 |
| SA520420768B1 (en) | 2022-08-30 |
| WO2019241533A1 (en) | 2019-12-19 |
| JP2023138672A (en) | 2023-10-02 |
| KR20210019507A (en) | 2021-02-22 |
| JOP20200304A1 (en) | 2020-11-25 |
| EA202092719A1 (en) | 2021-03-16 |
| EP3807281A1 (en) | 2021-04-21 |
| IL278949A (en) | 2021-01-31 |
| PE20211389A1 (en) | 2021-07-27 |
| NI202000098A (en) | 2021-05-28 |
| US10745392B2 (en) | 2020-08-18 |
| US20190382398A1 (en) | 2019-12-19 |
| ECSP20079861A (en) | 2021-03-31 |
| CN112262142B (en) | 2023-11-14 |
| AU2019285184A1 (en) | 2021-01-28 |
| CR20200613A (en) | 2021-06-10 |
| CN112262142A (en) | 2021-01-22 |
| BR112020024729A2 (en) | 2021-03-23 |
| US11325902B2 (en) | 2022-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA48583A (en) | BENZENE SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | |
| MA52888A (en) | BENZENE SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | |
| MA53489A (en) | HETEROARYL SUBSTITUTED SULPHONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | |
| MA52189A (en) | BENZOTHIOPHENS AND ASSOCIATED COMPOUNDS USED AS STING AGONISTS | |
| MA52486A (en) | PYRIDAZINONES USED AS PARP7 INHIBITORS | |
| MA45377A (en) | HETEROCYCLIC COMPOUNDS AS ANTIBACTERIAL AGENTS | |
| FR24C1001I1 (en) | ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTIC AND DIAGNOSTIC AGENTS | |
| MA52421A (en) | PHARMACEUTICAL COMPOUNDS | |
| MA55198A (en) | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | |
| MA46196A (en) | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-TYPE RECEPTORS | |
| MA49017A (en) | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THE USE OF THESE AS THERAPEUTIC AGENTS | |
| MA55325A (en) | COMPOUNDS FOR THE TREATMENT OF PD-L1 DISEASES | |
| MA52856A (en) | MERGED HETERARYL OR ARYL BICYCLIC COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | |
| MA52754A (en) | HETEROCYCLIC TRICYCLIC COMPOUNDS AS STING ACTIVATORS | |
| MA53377A (en) | PYRIDIN-2-ONE COMPOUNDS USEFUL AS SMARCA2 ANTAGONISTS | |
| MA54567A (en) | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | |
| MA50045A (en) | SPIROCYCLIC COMPOUNDS AND METHODS FOR THE PREPARATION AND USE OF THE SAME | |
| MA56183A (en) | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | |
| MA53086A (en) | THIOPHENE CARBOXAMIDES AND SUBSTITUTED ANALOGUES USED AS ANTIBACTERIAL AGENTS | |
| MA52244A (en) | PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS MODULATORS OF THE GLUN2B RECEPTOR | |
| MA48942A (en) | THERAPEUTIC COMPOUNDS, ASSOCIATED COMPOSITIONS AND METHODS OF USE | |
| MA51224A (en) | SULFONAMIDE COMPOUNDS AND THEIR USE | |
| MA53488A (en) | HETEROARYL SUBSTITUTED SULPHONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL BLOCKERS | |
| MA50041A (en) | SPIROCYCLIC COMPOUNDS AND METHODS FOR THE PREPARATION AND USE OF THE SAME | |
| MA46546A (en) | THERAPEUTIC COMPOUNDS AND THEIR METHODS OF USE |